A Correction in Echo Therapeutics’ Favor & Big Cancer News From BioTime
First, I need to correct some bad numbers I gave you in the last alert. I grossly underestimated the size of the Botox market when calculating the market potential of Echo Therapeutics Inc. Also, I've gotten a very thoughtful e-mail from a reader concerned about the recent market downturn. I think it's time for me to once again briefly restate the big-picture logic behind investing in disruptive emerging technologies. I've also got a teaser regarding BioTime's cancer subsidiary, OncoCyte.
You Must Be A Subscriber To View This Content.
If you are already a subscriber, click the login button below to get access. Not yet a subscriber? Checkout our publication below and get access today!
Breakthrough Technology Alert
This is the best time to be investing in world-changing technologies, as unprecedented innovations are taking off right now… Breakthrough Technology Alert tirelessly researches these exciting new breakthrough technologies to keep you well informed, outline specific opportunities, and keep you ahead of the game.